MUMBAI, India, Jan. 23 -- Intellectual Property India has published a patent application (202521105114 A) filed by Indian Institute Of Technology, Maharashtra, on Oct. 30, 2025, for 'non-viral gene delivery system for in situ modification of macrophages for solid tumor treatment.'
Inventor(s) include Prakriti Tayalia; and Armaan Mohammed Ameen Siddiqui.
The application for the patent was published on Jan. 23, under issue no. 04/2026.
According to the abstract released by the Intellectual Property India: "Non-Viral Gene Delivery System for In Situ Modification of Macrophages for solid tumor treatment. Disclosed herein is a non-viral gene delivery system for the in situ modification of macrophages to target solid tumors. The system comprises a polyplex formed by complexing a biocompatible cationic polymer with plasmid DNA and an immune-modulating agent. The plasmid encodes a chimeric antigen receptor (CAR) that specifically recognizes programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule commonly overexpressed in solid tumors, and is complexed with a cationic polymer system targeted for macrophages. The combination of CAR polyplex and the immune-modulating agent has shown a potent therapeutic effect on solid tumor when administered in vivo. This in situ delivery strategy obviates the need for ex vivo cell manipulation, providing a scalable, minimally invasive, and cost-effective alternative to conventional CAR-based therapies."
Disclaimer: Curated by HT Syndication.
